{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107314","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.462470+00:00","generated_at":"2026-05-15T11:21:08.906453+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events","bullets":["Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.","Decision follows slipped capital femoral epiphysis (SCFE) events in two investigator-sponsored trials; SCFE not seen in BioMarin's own trials or in >5,000 achondroplasia patients.","Phase 2 CANOPY trials for Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency will continue as planned.","Over 10,000 patient-years of safety data in achondroplasia shows no SCFE cases; VOXZOGO remains approved for achondroplasia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107314","json":"https://secwatch.observer/filing/0001193125-26-107314.json","markdown":"https://secwatch.observer/filing/0001193125-26-107314.md","text":"https://secwatch.observer/filing/0001193125-26-107314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/0001193125-26-107314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/d114815d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:21:08.906453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}